Marc Ernstoff, MD | Authors

Articles

PFS and Safety With Nivolumab Plus Ipilimumab in Advanced Melanoma

July 17, 2015

Marc Ernstoff, MD, director of melanoma, Cleveland Clinic, discusses progression-free survival (PFS) and safety in patients with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI).